Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anbenitamab - Alphamab

Drug Profile

Anbenitamab - Alphamab

Alternative Names: anti-HER2-bsAb - Alphamab; KN-026

Latest Information Update: 07 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alphamab
  • Developer Jiangsu Alphamab Biopharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Gastric cancer
  • Phase II Breast cancer; HER2 positive breast cancer; Solid tumours

Most Recent Events

  • 20 Oct 2023 Safety and efficacy data from a phase II trial in HER2-positive breast cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 20 Oct 2023 Updated efficacy and adverse event data from a phase II in HER2-positive breast cancer presented at the 48th European Society for Medical Oncology Congress 2023 (ESMO-2023)
  • 01 Sep 2023 Peking University plans a phase II trial for Gastric cancer (Combination therapy, Late-stage disease) (NCT06023758)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top